Theravance Biopharma

TBPH77

High Growth

$9.47arrow_drop_down1.50%-$0.14

High Growth

TBPH77

$9.47

arrow_drop_down1.50%-$0.14

High Growth

Performance History

Key Stats
Open	$9.59
Prev. Close	$9.61
EPS	-1.03
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	9.37	9.76
52 Week Range	7.44	11.71

Ratios







EPS	-1.03

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Theravance Biopharma (TBPH)

Theravance Biopharma Inc (TBPH) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule medicines for various therapeutic areas. The company's primary goal is to improve the lives of patients suffering from serious illnesses through innovative treatments. With a strong commitment to scientific excellence and patient-centricity, Theravance Biopharma is dedicated to advancing its pipeline of novel drug candidates. The company's efforts are driven by a deep understanding of disease biology and a focus on developing targeted therapies that address the underlying causes of disease.

Theravance Biopharma's stock price history reflects the dynamic nature of the biopharmaceutical industry. The company has experienced periods of volatility, with its stock price influenced by various factors such as clinical trial results, regulatory decisions, and market conditions. Investors interested in Theravance Biopharma can track its stock performance over time to assess its growth potential and investment opportunities. It is important to note that past performance is not indicative of future results, and investors should conduct their own research and analysis before making investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Rick E. Winningham M.B.A.
Headquarters: George Town
Employees: 111
Exchange: NASDAQ

Keep an eye on Theravance Biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Theravance Biopharma 's (TBPH) price per share?

The current price per share for Theravance Biopharma (TBPH) is $9.47. The stock has seen a price change of -$0.14 recently, indicating a -1.51% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Theravance Biopharma (TBPH)?

For Theravance Biopharma (TBPH), the 52-week high is $11.71, which is 23.65% from the current price. The 52-week low is $7.44, the current price is 27.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Theravance Biopharma (TBPH) a growth stock?

Theravance Biopharma (TBPH) has shown an average price growth of -3.66% over the past three years. It has received a score of 55 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Theravance Biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Theravance Biopharma (TBPH) stock price performance year to date (YTD)?

As of the latest data, Theravance Biopharma (TBPH) has a year-to-date price change of -18.29%. Over the past month, the stock has experienced a price change of 9.73%. Over the last three months, the change has been 17.06%. Over the past six months, the figure is 10.76%. Looking at a longer horizon, the five-year price change stands at -48.81%.

help

Is Theravance Biopharma (TBPH) a profitable company?

Theravance Biopharma (TBPH) has a net income of -$55.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 29.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -54.99% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $57.42M, with a revenue growth rate of 11.84%, providing insight into the company's sales performance and growth. The gross profit is $16.8M. Operating income is noted at -$53.29M. Furthermore, the EBITDA is -$38.24M.

help

What is the market capitalization of Theravance Biopharma (TBPH)?

Theravance Biopharma (TBPH) has a market capitalization of $460.56M. The average daily trading volume is 9.52, indicating the stock's liquidity and investor engagement.